Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
BioSpace
After entering the CAR T space in February, Eli Lilly is "jumping into in vivo CAR-T with both feet" with the acquisition of Kelonia Therapeutics and its gene delivery technology.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
BioSpace
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.
